Highlight
– Oral lamivudine, an inexpensive inflammasome inhibitor, significantly improves visual acuity in patients with center-involved diabetic macular edema (CI-DME).
– Lamivudine demonstrated superior visual improvement compared to intravitreous bevacizumab and ranibizumab, and comparable efficacy to aflibercept.
– The treatment was well tolerated with no significant differences in adverse events or retinal thickness compared to placebo.
Study Background and Disease Burden
Specialty calculators
For clinical reference; use professional judgment.
